In a recent trial, 80% of patients with (MRD)-positive acute lymphoblastic leukemia (ALL) who were treated with a drug called Blincyto (blinatumomab) achieved a complete response.

The FDA has approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread, but that continues to grow despite treatment with hormone therapy.

The Scottish Medicines Consortium (SMC) has approved Mavenclad (cladribine) as a treatment for highly active relapsing multiple sclerosis.

In 2015, an estimated 221,200 people in the U.S. will be diagnosed with lung cancer, which is 13 percent of all cancer diagnoses.

Scientists experimenting with an innovative treatment for cancer have now devised a targeted injection that has already successfully eliminated tumours in mice.

The first ever patient to be treated with a new type of CAR-T cell therapy in a novel clinical trial is now in remission.

Remember the hypospray from Star Trek? Maybe it's close to reality.

A new combination of medicines is showing positive results in ER/HER2-Positive breast cancer.

The experimental drug from Roche (balovaptan) has now been given Breakthrough Therapy Designation, potentially placing the drug on a faster path to market as the first pharmacological treatment for autism spectrum disorder (ASD). Pharmatimes, 30/01/2018.

Following the EMA’s approval in late 2017, the FDA has now also approved Lutathera (lutetium Lu 177 dotatate) for certain digestive tract cancers.

The potential of neuroprotective agents for a whole new form of treatment.

A list of medicines TheSocialMedwork will soon be making available.

New test detects ovarian and 7 other cancers using simple blood sample.

Brentuximab vedotin (Adcetris) has now been approved by the European Commission for the treatment of patients with CD30-positive cutaneous T-cell lymphoma (CTCL) who have had at least 1 prior systemic therapy.

Lynparza (olaparib) is the first PARP inhibitor approved to treat breast cancer, and the first medicine ever for metastatic breast cancer who have a “BRCA” gene mutation.

Ocrevus (ocrelizumab), the first ever FDA approved medicine for primary progressive MS has now also been approved by the EMA.

A new study found that cabozantinib (Cabometyx) was more effective than everolimus in advanced renal cell carcinoma and bone metastases.

A groundbreaking year helping patients access the latest approved medicines.

Pembrolizumab showed positive results in heavily pretreated, PD-L1–positive advanced esophageal carcinoma.

Specific strains of intestinal bacteria can improve the response rate to immunotherapy for patients being treated for advanced melanoma.

Eight important updates in lung cancer.

Darzalex (daratumumab) combination under review as first-line option.

Immunotherapy nivolumab has been linked to HIV reservoir decrease in a lung cancer patient. 

In a pilot study immunotherapy proved active in some patients with metastatic, trastuzumab (Herceptin)-resistant HER2-positive breast cancer.

Is there substance to the claims that it's a groundbreaking treatment?

Researchers are suggesting that metastatic tumours in the lung can be successfully eradicated using cryotherapy – literally turning the masses into ice balls that are then resorbed by the body.

The FDA has approved the first biosimilar for the treatment of certain breast and stomach cancers.

Mavenclad (cladribine) has become the multiple sclerosis therapy of choice for 1 in 5 neurologists in Germany and the UK. Meanwhile, many European neurologists wait for Ocrevus (ocrelizumab).

A phase 3 study on lung cancer showed that Imfinzi (durvalumab) as a consolidation therapy reduced the risk of the disease progressing by 48 percent.

FDA approves Juluca (dolutegravir and rilpivirine) for the maintenance treatment of certain patients with HIV-1 infection.